🇺🇸 FDA
Pipeline program

Aceneuramic Acid Extended-Release

UX001-CL203

Phase 2 small_molecule terminated

Quick answer

Aceneuramic Acid Extended-Release for Hereditary Inclusion Body Myopathy is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Hereditary Inclusion Body Myopathy
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials